Repetitive Transcranial Magnetic Stimulation in Cancer Pain Management

Официальное название

Feasibility and Effectiveness of Repetitive Transcranial Magnetic Stimulation in Patients With Cancer Pain

Обзор

Over half of cancer patients experience cancer-related pain. Despite advances in pain management with opioids, many patients continue to suffer from chronic cancer pain. The underlying mechanisms of cancer-related pain remain poorly understood, but they may be linked to brain neuroplasticity. As a result, some researchers suggest that targeting the motor cortex in cancer patients could improve pain management. However, few studies have investigated the effectiveness of remodeling neuroplasticity with repetitive transcranial magnetic stimulation (rTMS) to reduce cancer-related pain. To validate the use of rTMS in cancer-related pain, we plan to conduct a randomized controlled trial involving 30 cancer pain patients. Participants will be randomly assigned to receive either rTMS or sham rTMS treatment. Functional magnetic resonance imaging (fMRI) and pain index assessments will be conducted before and after the treatment to evaluate the outcomes.

Вмешательства

• Устройство Repetitive transcranial magnetic stimulation (rTMS)
  Repetitive transcranial magnetic stimulation toward for cancer pain (real and sham control)

Первичные конечные точки

• Brief Pain Inventory, BPI [Срок оценки: Assess the BPI outcome before the intervention, after 1 week and 2 weeks of intervention, as well as 1 week and 4 weeks after the intervention is completed.]
• McGill Pain Questionnaire [Срок оценки: Assess MPQ scores before the intervention, after 1 week and 2 weeks of intervention, as well as 1 week and 4 weeks after the intervention is completed.]

Вторичные конечные точки (5)

• Numerical Rating Scale, NRS [Срок оценки: Assess the NRS scale before the intervention, after 1 week and 2 weeks of intervention, as well as 1 week and 4 weeks after the intervention is completed.]
• Visual Analogue Scale , VAS [Срок оценки: Assess the VAS scale before the intervention, after 1 week and 2 weeks of intervention, as well as 1 week and 4 weeks after the intervention is completed.]
• Resting-state functional imaging, rsfMRI [Срок оценки: Assess the fMRI results before the intervention and after 2 weeks of interventions.]
• Beck Depression Inventory, BDI [Срок оценки: Assess the BDI scale before the intervention, after 1 week and 2 weeks of intervention, as well as 1 week and 4 weeks after the intervention is completed.]
• The 36-Item Short Form Survey quality of life [Срок оценки: Assess the The SF-36 outcome before the intervention, after 1 week and 2 weeks of intervention, as well as 1 week and 4 weeks after the intervention is completed.]

Критерии участия

Критерии включения

• Patients have cancer pain symptoms, confirmed by a physician as cancer pain or neuropathic cancer pain
• Experienced the worst pain NRS score ≥ 4
• The patient demonstrate good cognition and is able to cooperate with the assessment of pain severity.
• The estimated survival time exceeds 3 months.
• Pre-existing bisphosphonate, chemotherapy, and hormonal therapy regimens remained unchanged throughout the study.

Критерии исключения

• Individuals who have undergone head surgery or have metal implants in the head.
• Individuals with implanted cardiac pacemakers or cochlear prostheses.
• Have a history of epilepsy.
• Patients diagnosed with primary brain tumors or metastatic brain lesions.
• Present with additional neurological, psychiatric, or severe medical disorders.
• Individuals with metallic implants located in the cranial or cervical regions.
• Women who are pregnant.
• Presence of acute pain in any body region attributable to other medical conditions. -

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Двойное слепое

Основная цель

Лечение

Центры проведения

Тайвань · 1 центр

• Taipei Medical University Hospital — Taipei

Идентификаторы

NCT: NCT06949618 · N202209046

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗